Sign In
Buy ELVN
$59.42
-1.04 (-1.72%)
At Close: Aug 10, 2026
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-00
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
04:05pm, Thursday, 07'th May 2026
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Strong balance sheet with $452 million in cash, cash
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
12:26pm, Saturday, 28'th Mar 2026
Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduc
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Here’s Why
01:59am, Sunday, 22'nd Mar 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $31.76 and last traded at $30.05, with a volu
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts
01:31am, Saturday, 21'st Mar 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
04:05pm, Tuesday, 03'rd Mar 2026
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
04:05pm, Wednesday, 25'th Feb 2026
BOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of “Moderate Buy” by Brokerages
04:10am, Saturday, 21'st Feb 2026
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock,
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast
01:34am, Thursday, 05'th Feb 2026
Heron Therapeutics (NASDAQ: HRTX - Get Free Report) and Enliven Therapeutics (NASDAQ: ELVN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
12:58am, Sunday, 01'st Feb 2026
Enliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share. The sale repr
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
04:52am, Saturday, 24'th Jan 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) insider Joseph Lyssikatos sold 20,000 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average p
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
04:04am, Thursday, 15'th Jan 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) COO Anish Patel sold 48,300 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were sold at an ave
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars
02:16pm, Thursday, 08'th Jan 2026
Enliven Therapeutics Inc. (NASDAQ: ELVN) stock is trading higher on Thursday, with a session volume of 6.61 million compared to the average volume of 631.52 thousand as per data from Benzinga Pro.
Stocks Mixed as Defense Sector Charges Higher
12:15pm, Thursday, 08'th Jan 2026
Stocks are mixed as defense stocks surge, with the Dow Jones Industrial Average (DJI) up triple digits, while the Nasdaq Composite (IXIC) slides alongside tech
